Roche acquires immuno-oncology biotech Tusk in €655m deal

pharmafile | October 1, 2018 | News story | Sales and Marketing Droia, Roche, Tusk, immuno-oncology, immunology, oncology 

Swiss multinational Roche has acquired the privately held immuno-oncology company Tusk Therapeutics in a deal that could be worth up to €655 million.

Founded by Droia Oncology Ventures in 2014, Tusk have developed an antibody with a novel mode of action aimed at depleting regulatory T-cells (Tregs), which suppress immune responses towards cancer. Tusk’s antibody specifically depletes these harmful Tregs while leaving those other immune cells acting against the tumour alone.

Tusk’s technology is expected to start clinical trials towards the end of 2019.

Advertisement

Luc Dochez, Chief Executive Officer of Tusk Therapeutics, said: “We are delighted that Roche will further develop this novel antibody and drive the development ahead. The remaining portfolio of our immune-oncology targets will be further developed by Black Belt Therapeutics, a newly formed company spun out of Tusk Therapeutics.”

The deal involves an upfront payment of €70 million plus additional contingent payments of up to €585 million based on the achievement of certain predetermined milestones.

Louis Goss

Related Content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

The Gateway to Local Adoption Series

Latest content